Statistics from Altmetric.com
Commentary on: OpenUrl.
Over the last 20 years, little has changed in terms of HIV treatment paradigm, being a three-drug regimen the standard of care for initial therapy. However, for reasons of virological plausibility, toxicity and costs, clinical researchers have explored the alternatives of switching virologically controlled patients to less-drug regimens (ie, dual or monotherapy). Several randomised trials1 investigated the ritonavir-boosted protease inhibitor monotherapy (PI-mono), on the grounds of absence of resistance mutations …
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.